In This Article:
Over the last 7 days, the United States market has remained flat, yet it is up 32% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and scalability in a rapidly evolving sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 23.83% | 24.32% | ★★★★★★ |
| Ardelyx | 25.24% | 69.64% | ★★★★★★ |
| Sarepta Therapeutics | 24.00% | 42.49% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.35% | 70.33% | ★★★★★★ |
| Clene | 78.50% | 60.16% | ★★★★★★ |
| TG Therapeutics | 34.66% | 56.98% | ★★★★★★ |
| Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
| Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 247 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Blueprint Medicines
Simply Wall St Growth Rating: ★★★★★★
Overview: Blueprint Medicines Corporation is a precision therapy company that develops medicines for genomically defined cancers and blood disorders, with a market cap of $6.12 billion.
Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to $434.42 million. As a precision therapy developer, it focuses on creating treatments for genomically defined cancers and blood disorders both in the U.S. and internationally.
Blueprint Medicines, amid a challenging landscape, has shown remarkable resilience with its revenue surging by 25.5% annually, outpacing the US market's growth of 8.9%. This growth trajectory is supported by significant R&D investments that underscore its commitment to innovation in tackling complex diseases. The firm's recent adjustment in revenue guidance to $475-$480 million for AYVAKIT reflects a robust demand and operational excellence. Despite current unprofitability, Blueprint is poised for profitability within three years with earnings expected to grow at an impressive rate of 68.6% per year, highlighting its potential in transforming patient outcomes through scientific breakthroughs.
-
Get an in-depth perspective on Blueprint Medicines' performance by reading our health report here.
-
Evaluate Blueprint Medicines' historical performance by accessing our past performance report.
Roku
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market capitalization of approximately $10.02 billion.
Operations: Roku generates revenue primarily through its Platform segment, which accounts for $3.32 billion, and the Devices segment, contributing $579.97 million. The Platform segment is a significant driver of Roku's business model.